Know Your Myeloma Therapy: What's Available for Consolidation Therapy? image

Know Your Myeloma Therapy: What's Available for Consolidation Therapy?

Mar 08, 2023
07:00PM - 08:00PM EST
Online Event
Overview

Myeloma specialist Dr. Sam Rubinstein joins us to share the answers to questions like: Is consolidation therapy used in every myeloma patient, and if not, why? 

What treatment regimens are normal for consolidation therapy and how long do they last? 

And what is the end goal of consolidation therapy? Find out the answer to these questions and more of your own by attending our event!

Agenda
7:00 PM
Introductions
Audrey Burton-Bethke

Audrey introduces the agenda of the event and featured speaker Dr. Rubinstein.

7:05 PM
Presentation
Dr. Samuel Rubinstein

Dr. Rubinstein joins us to share the answers to questions like: Is consolidation therapy used in every myeloma patient, and if not, why? 

7:35 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Dr. Samuel Rubinstein

Dr. Samuel Rubinstein

Dr. Rubinstein is an assistant professor and malignant hematologist at the University of North Carolina Chapel Hill and an associate member of the Lineberger Comprehensive Cancer Center. His primary clinical and research area of interest is plasma cell dyscrasias, and he is focused on clinical trials designed to improve the standard of care of patients with these disorders. In addition to clinical trials, Dr. Rubinstein has an informatics background, which he has leveraged to develop multiple prognostic scoring tools that are useful in the management of patients with plasma cell dyscrasias. During the COVID-19 pandemic, Dr. Rubinstein also developed an interest in the impacts of COVID-19 on patients with cancer. He serves as the site PI of the COVID-19 and cancer consortium (CCC19) at UNC, and in this capacity has contributed to a number of studies derived from CCC-19 data to answer clinically relevant questions about the epidemiology and outcomes of patients with cancer and COVID-19.